14,883 Shares in Bioventus Inc. (NYSE:BVS) Bought by Seizert Capital Partners LLC

Seizert Capital Partners LLC purchased a new position in shares of Bioventus Inc. (NYSE:BVS) in the fourth quarter, HoldingsChannel reports. The institutional investor purchased 14,883 shares of the company’s stock, valued at approximately $156,000.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Plato Investment Management Ltd purchased a new position in Bioventus in the 4th quarter valued at about $38,000. Virtus Fund Advisers LLC purchased a new position in Bioventus in the 3rd quarter valued at about $42,000. Quest Partners LLC purchased a new position in Bioventus in the 3rd quarter valued at about $51,000. Quarry LP purchased a new position in Bioventus in the 3rd quarter valued at about $59,000. Finally, Covestor Ltd purchased a new position in Bioventus in the 3rd quarter valued at about $69,000. 62.94% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. JPMorgan Chase & Co. raised shares of Bioventus from an “underweight” rating to a “neutral” rating and upped their price objective for the company from $12.00 to $13.00 in a research report on Tuesday, December 17th. Canaccord Genuity Group upped their price objective on shares of Bioventus from $12.00 to $15.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th.

Insider Activity

In related news, CEO Robert E. Claypoole sold 28,786 shares of the stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $9.10, for a total transaction of $261,952.60. Following the sale, the chief executive officer now owns 64,964 shares in the company, valued at $591,172.40. This represents a 30.71 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Mark Leonard Singleton sold 10,733 shares of the stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $10.53, for a total transaction of $113,018.49. Following the sale, the chief financial officer now owns 105,162 shares in the company, valued at approximately $1,107,355.86. This trade represents a 9.26 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 52,932 shares of company stock worth $512,511. 32.90% of the stock is currently owned by corporate insiders.

Bioventus Stock Performance

Shares of Bioventus stock opened at $10.19 on Thursday. The firm has a market cap of $826.97 million, a PE ratio of -16.70 and a beta of 0.86. The firm’s 50-day simple moving average is $10.22 and its 200-day simple moving average is $10.99. The company has a debt-to-equity ratio of 1.85, a quick ratio of 0.99 and a current ratio of 1.41. Bioventus Inc. has a 1 year low of $3.90 and a 1 year high of $14.38.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.